BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35759947)

  • 21. The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study.
    Vranceanu AM; Merker VL; Plotkin SR; Park ER
    J Neurooncol; 2014 Oct; 120(1):103-9. PubMed ID: 25022450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis.
    Merker VL; Bredella MA; Cai W; Kassarjian A; Harris GJ; Muzikansky A; Nguyen R; Mautner VF; Plotkin SR
    Am J Med Genet A; 2014 Jun; 164A(6):1431-7. PubMed ID: 24664633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1.
    Evans DGR; Salvador H; Chang VY; Erez A; Voss SD; Schneider KW; Scott HS; Plon SE; Tabori U
    Clin Cancer Res; 2017 Jun; 23(12):e46-e53. PubMed ID: 28620004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.
    Banerjee J; Friedman JM; Klesse LJ; Yohay KH; Jordan JT; Plotkin SR; Allaway RJ; Blakeley JO
    Genet Med; 2023 Feb; 25(2):100324. PubMed ID: 36565307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plexiform neurofibroma: shedding light on the investigational agents in clinical trials.
    Acar S; Armstrong AE; Hirbe AC
    Expert Opin Investig Drugs; 2022 Jan; 31(1):31-40. PubMed ID: 34932916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation.
    Plotkin SR; Messiaen L; Legius E; Pancza P; Avery RA; Blakeley JO; Babovic-Vuksanovic D; Ferner R; Fisher MJ; Friedman JM; Giovannini M; Gutmann DH; Hanemann CO; Kalamarides M; Kehrer-Sawatzki H; Korf BR; Mautner VF; MacCollin M; Papi L; Rauen KA; Riccardi V; Schorry E; Smith MJ; Stemmer-Rachamimov A; Stevenson DA; Ullrich NJ; Viskochil D; Wimmer K; Yohay K; ; Huson SM; Wolkenstein P; Evans DG
    Genet Med; 2022 Sep; 24(9):1967-1977. PubMed ID: 35674741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.
    Ahlawat S; Fayad LM; Khan MS; Bredella MA; Harris GJ; Evans DG; Farschtschi S; Jacobs MA; Chhabra A; Salamon JM; Wenzel R; Mautner VF; Dombi E; Cai W; Plotkin SR; Blakeley JO; ;
    Neurology; 2016 Aug; 87(7 Suppl 1):S31-9. PubMed ID: 27527647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing biologically targeted clinical trials for neurofibromatosis.
    Gutmann DH; Blakeley JO; Korf BR; Packer RJ
    Expert Opin Investig Drugs; 2013 Apr; 22(4):443-62. PubMed ID: 23425047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Neurofibromatosis].
    Wolkenstein P; Decq P
    Neurochirurgie; 1998 Nov; 44(4):267-72. PubMed ID: 9864698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas: Implications for Clinical Trials.
    Cannon A; Pichard DC; Wolters PL; Adsit S; Erickson G; Lessing AJ; Li P; Narmore W; Röhl C; Rosser T; Widemann BC; Blakeley JO; Plotkin SR;
    Neurology; 2021 Aug; 97(7 Suppl 1):S15-S24. PubMed ID: 34230202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imaging Evaluation of Plexiform Neurofibromas in Neurofibromatosis Type 1: A Survey-Based Assessment.
    Ahlawat S; Ly KI; Fayad LM; Fisher MJ; Lessing AJ; Berg DJ; Salamon JM; Mautner VF; Babovic-Vuksanovic D; Dombi E; Harris G; Plotkin SR; Blakeley J;
    Neurology; 2021 Aug; 97(7 Suppl 1):S111-S119. PubMed ID: 34230200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Schwannomatosis: the overlooked neurofibromatosis?
    Koontz NA; Wiens AL; Agarwal A; Hingtgen CM; Emerson RE; Mosier KM
    AJR Am J Roentgenol; 2013 Jun; 200(6):W646-53. PubMed ID: 23701098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of mental health on health-related quality of life in patients with NF2-related Schwannomatosis.
    Freier A; Lawson McLean AC; Loeschner D; Rosahl SK; Kruse J
    Sci Rep; 2024 Mar; 14(1):6934. PubMed ID: 38521834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurofibromatoses: part 1 - diagnosis and differential diagnosis.
    Rodrigues LO; Batista PB; Goloni-Bertollo EM; de Souza-Costa D; Eliam L; Eliam M; Cunha KS; Darrigo-Junior LG; Ferraz-Filho JR; Geller M; Gianordoli-Nascimento IF; Madeira LG; Malloy-Diniz LF; Mendes HM; de Miranda DM; Pavarino EC; Baptista-Pereira L; Rezende NA; Rodrigues Lde O; da Silva CM; de Souza JF; de Souza ML; Stangherlin A; Valadares ER; Vidigal PV
    Arq Neuropsiquiatr; 2014 Mar; 72(3):241-50. PubMed ID: 24676443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurofibromatosis- and schwannomatosis-associated tumors: Approaches to genetic testing and counseling considerations.
    Goetsch Weisman A; Weiss McQuaid S; Radtke HB; Stoll J; Brown B; Gomes A
    Am J Med Genet A; 2023 Oct; 191(10):2467-2481. PubMed ID: 37485904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trials.
    Staedtke V; Anstett K; Bedwell D; Giovannini M; Keeling K; Kesterson R; Kim Y; Korf B; Leier A; McManus ML; Sarnoff H; Vitte J; Walker JA; Plotkin SR; Wallis D
    Clin Trials; 2024 Feb; 21(1):51-66. PubMed ID: 37937606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Available Therapies for Patients with Neurofibromatosis-Related Nervous System Tumors.
    Strowd RE
    Curr Treat Options Oncol; 2020 Aug; 21(10):81. PubMed ID: 32767156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic Counseling for Neurofibromatosis 1, Neurofibromatosis 2, and Schwannomatosis-Practice Resource of the National Society of Genetic Counselors.
    Radtke HB; Bergner AL; Goetsch AL; McGowan C; Panzer K; Cannon A
    J Genet Couns; 2020 Oct; 29(5):692-714. PubMed ID: 32602153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pediatric schwannomatosis, a rare but distinct form of neurofibromatosis.
    Thomas AK; Egelhoff JC; Curran JG; Thomas B
    Pediatr Radiol; 2016 Mar; 46(3):430-5. PubMed ID: 26546566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution.
    Li P; Zhao F; Zhang J; Wang Z; Wang X; Wang B; Yang Z; Yang J; Gao Z; Liu P
    J Neurosurg Spine; 2016 Jan; 24(1):145-54. PubMed ID: 26407091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.